Evidence map›Paper›PMID 26124495›Full record

ArticleBlood2015

Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells.

Alexandra C Vrazo, Adrianne E Hontz, Sarah K Figueira, Braeden L Butler, Julie M Ferrell, Brock F Binkowski, Jinzhu Li, Kimberly A Risma

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Development of ZFrontiers in immunology · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Immune evasion by cancer stem cells.Regenerative therapy · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alexandra C VrazoDivision of Allergy/Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH;ORCID http://orcid.org/0000-0002-7216-9302
Adrianne E HontzDivision of Allergy/Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH;ORCID http://orcid.org/0000-0002-3656-7055
Sarah K FigueiraDivision of Allergy/Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH;
Braeden L ButlerPromega Corp, Madison, WI; and.
Julie M FerrellDivision of Allergy/Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH;
Brock F BinkowskiPromega Corp, Madison, WI; and.
Jinzhu LiDivision of Allergy/Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH;
Kimberly A RismaDivision of Allergy/Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Cincinnati Children's Hospital Medical Center · USPromega (United States) · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
Cincinnati Center for Clinical and Translational Sciences and TrainingUL1TR000077 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., TSEVAT, JOEL · 2012 to 2014
$9.9M
Immunology/Allergy Fellowship Training GrantT32AI060515 · NIAID · UNIVERSITY OF CINCINNATI · PI BERNSTEIN, DAVID I., ROTHENBERG, MARC E. · 2004 to 2018
$2.8M
NCATS NIH HHS 8 UL1 TR000077-05NCATS NIH HHS UL1 TR000077NCATS NIH HHS UL1 TR001425NIAID NIH HHS T32 AI-060515NIAID NIH HHS T32 AI060515
6 · The paper itself

Abstract

Growing interest in natural killer (NK) cell-based therapy for treating human cancer has made it imperative to develop new tools to measure early events in cell death. We recently demonstrated that protease-cleavable luciferase biosensors detect granzyme B and pro-apoptotic caspase activation within minutes of target cell recognition by murine cytotoxic lymphocytes. Here we report successful adaptation of the biosensor technology to assess perforin-dependent and -independent induction of death pathways in tumor cells recognized by human NK cell lines and primary cells. Cell-cell signaling via both Fc receptors and NK-activating receptors led to measurable luciferase signal within 15 minutes. In addition to the previously described aspartase-cleavable biosensors, we report development of granzyme A and granzyme K biosensors, for which no other functional reporters are available. The strength of signaling for granzyme biosensors was dependent on perforin expression in IL-2-activated NK effectors. Perforin-independent induction of apoptotic caspases was mediated by death receptor ligation and was detectable after 45 minutes of conjugation. Evidence of both FasL and TRAIL-mediated signaling was seen after engagement of Jurkat cells by perforin-deficient human cytotoxic lymphocytes. Although K562 cells have been reported to be insensitive to TRAIL, robust activation of pro-apoptotic caspases by NK cell-derived TRAIL was detectable in K562 cells. These studies highlight the sensitivity of protease-cleaved luciferase biosensors to measure previously undetectable events in live cells in real time. Further development of caspase and granzyme biosensors will allow interrogation of additional features of granzyme activity in live cells including localization, timing, and specificity.

Indexed as

Biosensing TechniquesApoptosisCaspasesCell Line, TumorEnzyme ActivationFlow CytometryGranzymesHumansImmunoblottingImmunotherapyJurkat CellsK562 CellsKiller Cells, NaturalNeoplasmsRecombinant ProteinsTransfectionCaspasesGranzymesRecombinant Proteins

Identifiers

PMID26124495
PMCPMC4543232
OpenAlexW2155004687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.